HIV-1 genetic diversity and transmitted drug resistance in health care settings in Maputo, Mozambique

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 3, 2009, Pages 323-331

  Bártolo, Inês ^a   Casanovas, José ^b   Bastos, Rui ^c   Rocha, Cheila ^a   Abecasis, Ana B ^d   Folgosa, Elena ^b   Mondlane, José ^b   Manuel, Rolanda ^c   Taveira, Nuno ^a,e  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b EDUARDO MONDLANE UNIVERSITY   (Mozambique)

^c MAPUTO CENTRAL HOSPITAL   (Mozambique)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^e INSTITUTO SUPERIOR DE CIÊNCIAS DA SAÚDE EGAS MONIZ   (Portugal)

Author keywords

HIV 1 genetic forms; HIV 1 infection in Maputo; Transmitted HIV 1 drug resistance

Indexed keywords

PROTEINASE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ALGORITHM; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; MOZAMBIQUE; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; PRIVATE HOSPITAL; PUBLIC HOSPITAL; VIREMIA; VIRUS LOAD; VIRUS MUTATION; DRUG EFFECT; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; MUTATION; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC VARIATION; HIV INFECTIONS; HIV-1; HOSPITALS, PUBLIC; HUMANS; MALE; MIDDLE AGED; MOZAMBIQUE; MUTATION; PHYLOGENY; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 67651031262     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181a24906     Document Type: Article

References (57)

1. Mencarini P, De Luca A, Ghirga P, et al. Human immunodeficiency virus type 1 infection in a community of southern Mozambique. Trop Geogr Med. 1991;43:39-41.
2. Barreto J, Liljestrand J, Palha de Sousa C, et al. HIV-1 and HIV-2 antibodies in pregnant women in the City of Maputo, Mozambique. A comparative study between 1982/1983 and 1990. Scand J Infect Dis. 1993;25:685-688.
3. Health MMo. Preliminary Results 2007 Sentinel Surveillance. 2008. Available at: http://www.sida.org.mz\. Accessed June 16 2008.
4. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998;352:1725-1730.
5. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
6. Sterne JA, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366:378-384.
7. Wester CW, Kim S, Bussmann H, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr. 2005;40: 336-343.
8. Weidle PJ, Downing R, Sozi C, et al. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative-Uganda. AIDS. 2003;17 (Suppl 3):S39-S48.
9. Katzenstein D, Laga M, Moatti JP. The evaluation of the HIV/AIDS drug access initiatives in Cote d'Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa. AIDS. 2003; 17(Suppl 3):S1-S4.
10. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-824.
11. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS. 2006;20: 1391-1399.
12. Fairall LR, Bachmann MO, Louwagie GM, et al. Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med. 2008; 168:86-93.
13. Jahn A, Floyd S, Crampin AC, et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet. 2008;371:1603-1611.
14. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006;368:505-510.
15. Nkengasong JN, Adje-Toure C, Weidle PJ. HIV antiretroviral drug resistance in Africa. AIDS Rev. 2004;6:4-12.
16. Gupta RK, Pillay D. HIV resistance and the developing world. Int J Antimicrob Agents. 2007;29:510-517.
17. Bennett DE, Bertagnolio S, Sutherland D, et al. World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther. 2008;13(Suppl 2):1-13.
18. Jordan MR, Bennett DE, Bertagnolio S, et al. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther. 2008; 13(Suppl 2): 15-23.
19. Vardavas R, Blower S. The emergence of HIV transmitted resistance in Botswana: "when will the WHO detection threshold be exceeded?" PLoS ONE. 2007;2:e152.
20. Geretti AM. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis. 2007;20:22-32.
21. Pillay V, Ledwaba J, Hunt G, et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther. 2008;13(Suppl 2): 101-107.
22. Maphalala G, Okello V, Mndzebele S, et al. Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006. Antivir Ther. 2008;13(Suppl 2):95-100.
23. Somi GR, Kibuka T, Diallo K, et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther. 2008;13(Suppl 2):77-82.
24. Kamoto K, Aberle-Grasse J. Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther. 2008;13(Suppl 2):83-87.
25. Abegaz WE, Grossman Z, Wolday D, et al. Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. Antivir Ther. 2008;13(Suppl 2):89-94.
26. van de Vijver D, Wensing A, Boucher C. The epidemiology of transmission of drug resistant HIV-1. In: Leitner T, Foley B, Hahn B, et al, eds. HIV Sequence Compendium 2006/2007. Los Alamos, New Mexico: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 2007:17-36.
27. Lahuerta M, Aparicio E, Bardaji A, et al. Rapid spread and genetic diversification of HIV type 1 subtype C in a rural area of southern Mozambique. AIDS Res Hum Retroviruses. 2008;24:327-335.
28. Bellocchi MC, Forbici F, Palombi L, et al. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme. J Med Virol. 2005;76:452-458.
29. Parreira R, Piedade J, Domingues A, et al. Genetic characterization of human immunodeficiency virus type 1 from Beira, Mozambique. Microbes Infect. 2006;8:2442-2451.
30. Bartolo I, Epalanga M, Bartolomeu J, et al. High genetic diversity of human immunodeficiency virus type 1 in Angola. AIDS Res Hum Retroviruses. 2005;21:306-310.
31. Bartolo I, Rocha C, Bartolomeu J, et al. Highly divergent subtypes and new recombinant forms prevail in the HIV/AIDS epidemic in Angola: new insights into the origins of the AIDS pandemic. Infect Genet Evol. 2008. [Epub ahead of print].
32. Database LAS. Los Alamos, et al. New Mexico: Los Alamos National Laboratory; 2008. Available at: http://www.hiv.lanl.gov/. Accessed September 2008.
33. Thompson JD, Gibson TJ, Plewniak F, et al. The CLUSTAL-X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 1997;25:4876-4882.
34. Felsenstein J. Evolutionary trees from DNA sequences: a maximum likelihood approach. J Mol Evol. 1981;17:368-376.
35. Posada D, Crandall KA. MODELTEST: testing the model of DNA substitution. Bioinformatics. 1998;14:817-818.
36. * and Other Methods) [computer program]. Version 4. Sunderland, MA: Sinauer-associates; 2001.
37. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution. 1985;39:783-791.
38. Hillis D, Bull J. An empirical test for bootscanning as a method for assessing viral sequence relatedness. Syst Biol. 1993;42: 182-192.
39. Lole KS, Bollinger RC, Paranjape RS, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol. 1999;73: 152-160.
40. Salemi M, Vandamme A.-M. The Phylogenetic Handbook: A Practical Approach to DNA and Protein Phylogeny. Cambridge, United Kingdom: Cambridge University Press; 2003.
41. Shafer R. Database SHDR. Stanford University, California; 2008. Available at: http://hivdb6.stanford.edu/. Accessed July 2008.
42. Shafer RW, Rhee SY, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007;21: 215-223.
43. Shafer RW, Rhee SY, Bennett DE. Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies. Antivir Ther. 2008;13(Suppl 2):59-68.
44. GraphPad Prism 4 [computer program]. Version 4.0. San Diego, California; 2003.
45. Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008;197:563-571.
46. Poveda E, de Mendoza C, Martin-Carbonero L, et al. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother. 2007;60:885-888.
47. de Meyer S, Vangeneugden T, van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses. 2008;24:379-388.
48. Baxter JD, Schapiro JM, Boucher CA, et al. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol. 2006;80:10794-10801.
49. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2003 revision. 2008. Available at: http://www.who.int/hiv/pub/prev-care/en/ arvrevision2003en.pdf. Accessed May 6, 2008.
50. Langford SE, Ananworanich J, Cooper DA. Predictors of disease progression in HIV infection: a review. AIDS Res Ther. 2007;4:11.
51. Gordon M, De Oliveira T, Bishop K, et al. Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies. J Virol. 2003;77:2587-2599.
52. Powell RL, Zhao J, Konings FA, et al. Circulating recombinant form (CRF) 37-cpx: an old strain in Cameroon composed of diverse, genetically distant lineages of subtypes A and G. AIDS Res Hum Retroviruses. 2007;23:923-933.
53. Meloni ST, Sankale JL, Hamel DJ, et al. Molecular epidemiology of human immunodeficiency virus type 1 sub-subtype A3 in Senegal from 1988 to 2001. J Virol. 2004;78:12455-12461.
54. Piyasirisilp S, McCutchan FE, Carr JK, et al. A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. J Virol. 2000;74: 11286-11295.
55. Peuchant O, Thiebaut R, Capdepont S, et al. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS. 2008;22:1417-1423.
56. Pearson CR, Micek M, Simoni JM, et al. Modified directly observed therapy to facilitate highly active antiretroviral therapy adherence in Beira, Mozambique. Development and implementation. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S134-S141.
57. Pearson CR, Micek MA, Simoni JM, et al. Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr. 2007;46:238-244.